- Trials with a EudraCT protocol (30)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
30 result(s) found for: Binimetinib.
Displaying page 1 of 2.
EudraCT Number: 2021-004395-34 | Sponsor Protocol Number: C4221026 | Start Date*: 2022-07-06 | ||||||||||||||||||||||||||
Sponsor Name:Pfizer Inc. | ||||||||||||||||||||||||||||
Full Title: ENCORAFENIB/BINIMETINIB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM ENCORAFENIB/BINIMETINIB CLINICAL STUDIES | ||||||||||||||||||||||||||||
Medical condition: solid tumors | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: NL (Ongoing) ES (Ongoing) IT (Ongoing) BE (Ongoing) SK (Ongoing) HU (Ongoing) CZ (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000271-32 | Sponsor Protocol Number: W00090GE201 | Start Date*: 2018-11-11 | |||||||||||
Sponsor Name:Pierre Fabre Médicament | |||||||||||||
Full Title: Phase II, open-label, single arm, multicenter study of encorafenib, binimetinib plus cetuximab in subjects with previously untreated BRAF V600E -mutant Metastatic Colorectal Cancer | |||||||||||||
Medical condition: BRAF V600E -mutant Metastatic Colorectal Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) ES (Ongoing) BE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) AT (Completed) IT (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004850-31 | Sponsor Protocol Number: C4221016 | Start Date*: 2021-07-29 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS PLACEBO PLUS PEMBROLIZUMAB IN PARTICIPANTS WITH BRAF V600E/K MUTATION-POSITIVE METASTATIC OR UNRES... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Metastatic or unresectable locally advanced BRAF V600E/K mutation positive melanoma | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Ongoing) HU (Ongoing) BG (Ongoing) IT (Ongoing) AT (Prematurely Ended) SK (Ongoing) CZ (Ongoing) NO (Prematurely Ended) PL (Ongoing) GR (Ongoing) FI (Ongoing) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000177-80 | Sponsor Protocol Number: DCC-2618-01-008 | Start Date*: 2021-08-17 |
Sponsor Name:Deciphera Pharmaceuticals, LLC | ||
Full Title: A Phase 1b/2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Ripretinib in Combination with Binimetinib in Patients with Gastrointestinal Str... | ||
Medical condition: Gastrointestinal Stromal Tumor (GIST) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2014-000463-40 | Sponsor Protocol Number: OCTO_049 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:University of Oxford | |||||||||||||
Full Title: A Sequential Phase I study of MEK1/2 inhibitors PD-0325901 or Binimetinib combined with cMET inhibitor Crizotinib in RAS Mutant and RAS Wild Type(with aberrant c-MET) Colorectal Cancer | |||||||||||||
Medical condition: Cancer. Solid tumours in the escalation phase and colorectal cancer in the expansion groups. | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000124-34 | Sponsor Protocol Number: B9991033 | Start Date*: 2019-02-19 | ||||||||||||||||
Sponsor Name:Pfizer Inc, 253 East 42nd Street, New York, NY 10017 | ||||||||||||||||||
Full Title: A Phase 1b/2, study to evaluate safety and clinical activity of avelumab in combination with binimetinib with or without talazoparib in patients with locally advanced or metastatic RAS-Mutant Solid... | ||||||||||||||||||
Medical condition: locally advanced or metastatic KRAS-or NRAS-mutant NSCLC, mPDAC (regardless of KRAS status), and other KRAS-or NRAS-mutant solid tumors | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-004555-21 | Sponsor Protocol Number: ARRAY-818-201 | Start Date*: 2019-07-08 | |||||||||||
Sponsor Name:Array BioPharma Inc. | |||||||||||||
Full Title: A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-Mutant Melanoma Brain Metastasis | |||||||||||||
Medical condition: BRAFV600-Mutant Melanoma Brain Metastasis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) NL (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001946-32 | Sponsor Protocol Number: ARRAY-162-115 | Start Date*: 2021-12-07 | |||||||||||
Sponsor Name:Array BioPharma Inc. | |||||||||||||
Full Title: A Multicenter, Open-label Phase Ib Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients with Unresectable or Metastatic BRAF V600-mutant Melanoma P/071/2018 | |||||||||||||
Medical condition: Unresectable or metastatic BRAF V600-mutant melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Ongoing) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004621-24 | Sponsor Protocol Number: IFCT-1904 | Start Date*: 2020-11-18 | ||||||||||||||||
Sponsor Name:IFCT | ||||||||||||||||||
Full Title: A Phase II study of the BRAF inhibitor Encorafenib in combination with the MEK inhibitor Binimetinib in Patients with BRAFV600E-mutant metastatic Non-small Cell Lung Cancer | ||||||||||||||||||
Medical condition: BRAFV600E-mutant metastatic Non-small Cell Lung Cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005805-35 | Sponsor Protocol Number: ARRAY-818-302 | Start Date*: 2016-11-28 | |||||||||||
Sponsor Name:Array BioPharma Inc. | |||||||||||||
Full Title: A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA) /Irino... | |||||||||||||
Medical condition: BRAF V600E-mutant Metastatic Colorectal Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) HU (Completed) BE (Completed) AT (Completed) NL (Completed) CZ (Completed) DK (Completed) ES (Ongoing) NO (Completed) DE (Completed) IT (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-004310-19 | Sponsor Protocol Number: W00090GE303/EORTC-2139-MG | Start Date*: 2022-04-19 | |||||||||||
Sponsor Name:Pierre Fabre Médicament | |||||||||||||
Full Title: Adjuvant encorafenib & binimetinib vs. placebo in fully resected stage IIB/C BRAF V600E/K mutated melanoma: a randomized triple-blind phase III study in collaboration with the EORTC Melanoma Group | |||||||||||||
Medical condition: Resected BRAF V600E/K stage IIB/C melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) NO (Completed) AT (Ongoing) NL (Prematurely Ended) PL (Ongoing) GR (Ongoing) CZ (Ongoing) HU (Ongoing) ES (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-006331-26 | Sponsor Protocol Number: UC-0107/1810 | Start Date*: 2022-02-15 | |||||||||||
Sponsor Name:UNICANCER | |||||||||||||
Full Title: Phase 2, randomised trial testing the addition of upfront stereotactic radiosurgery to binimetinib, encorafenib plus pembrolizumab in comparison with binimetinib, encorafenib plus pembrolizumab alo... | |||||||||||||
Medical condition: BRAF(V600) mutation-positive melanoma with brain metastasis (MBM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003464-12 | Sponsor Protocol Number: ARRAY-162-202 | Start Date*: 2018-01-08 | |||||||||||
Sponsor Name:Array BioPharma Inc. | |||||||||||||
Full Title: An Open-label Phase 1b/2 Study of Binimetinib Administered in Combination with Nivolumab or Nivolumab Plus Ipilimumab in Patients with Previously Treated Microsatellite-stable (MSS) Metastatic Colo... | |||||||||||||
Medical condition: Microsatellite-stable (MSS) Metastatic Colorectal Cancer with RAS Mutation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) NL (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000417-37 | Sponsor Protocol Number: ARRAY-818-202 | Start Date*: 2019-07-16 | |||||||||||
Sponsor Name:Array BioPharma Inc. | |||||||||||||
Full Title: A Phase 2, Open-label Study of Encorafenib + Binimetinib in Patients with BRAF V600E-mutant Non-small Cell Lung Cancer | |||||||||||||
Medical condition: BRAF V600E-mutant Non-small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) NL (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000743-41 | Sponsor Protocol Number: W00090GE302/EORTC-1902-MG | Start Date*: 2021-07-21 | |||||||||||
Sponsor Name:PIERRE FABRE MéDICAMENT | |||||||||||||
Full Title: Adjuvant encorafenib & binimetinib vs. placebo in resected stage II BRAF V600E/K mutated melanoma: a randomized triple-blind Phase III Study in collaboration with the EORTC Melanoma Group. | |||||||||||||
Medical condition: Resected BRAF V600E/K stage II melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002887-42 | Sponsor Protocol Number: EORTC-1612-MG | Start Date*: 2018-06-28 | |||||||||||
Sponsor Name:European Organisation for Research and Treatment of Cancer | |||||||||||||
Full Title: Combination of targeted therapy (encorafenib and binimetinib) followed by combination of immunotherapy (ipilimumab and nivolumab) vs immediate combination of immunotherapy in patients with unresect... | |||||||||||||
Medical condition: BRAF V600 mutation–positive unresectable or metastatic melanoma. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) DE (Ongoing) PL (Ongoing) NL (Ongoing) DK (Completed) ES (Ongoing) IT (Ongoing) FI (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002530-20 | Sponsor Protocol Number: GEM-1802 | Start Date*: 2019-03-12 | ||||||||||||||||
Sponsor Name:Grupo Español Multidisciplinar de Melanoma | ||||||||||||||||||
Full Title: Multicentric phase II clinical trial to evaluate the activity of encorafenib and binimetinib before local treatment in patients with BRAF mutated melanoma with metastasis to the brain. | ||||||||||||||||||
Medical condition: BRAF mutant melanoma metastatic to the brain | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004987-23 | Sponsor Protocol Number: RAS-Triplet | Start Date*: 2020-05-22 |
Sponsor Name:UMC Utrecht | ||
Full Title: A Dose-Escalating Phase I/II Study in Patients with RAS-Mutated Metastatic Colorectal Cancer to Investigate Safety and Clinical Activity of the Triple Combination of: MEK-inhibitor binimetinib, Pan... | ||
Medical condition: colorectal cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005771-12 | Sponsor Protocol Number: AIO-KRK-0420 | Start Date*: 2022-05-30 | ||||||||||||||||||||||||||
Sponsor Name:AIO-Studien-gGmbH | ||||||||||||||||||||||||||||
Full Title: Neoadjuvant encorafenib, binimetinib and cetuximab for patients with BRAF V600E mutated/pMMR localized colorectal cancer | ||||||||||||||||||||||||||||
Medical condition: Patients with unresected BRAFV600E mutated/pMMR localized colorectal cancer | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000875-34 | Sponsor Protocol Number: MM1807 | Start Date*: 2018-05-30 | |||||||||||
Sponsor Name:National Center for Cancer Immune Therapy | |||||||||||||
Full Title: Efficacy of immunotherapy in melanoma patients with brain metastases treated with steroids | |||||||||||||
Medical condition: Metastatic melanoma with brain metastasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.